Company profile
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
NASDAQ:KNSABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ARCALYST | approved | $243.6MQ2 2026 | 2 | approved |
| ABIPRUBART | phase2 | — | 3 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03980522 | phase2 | completed | 2018-01-24 | 2019-05-17 | Kiniksa Pharmaceuticals (UK), Ltd. | A Pilot Study of KPL-914 in Recurrent Pericarditis |
| NCT06531395 | phase2 | terminated | 2024-07-17 | 2025-03-06 | Kiniksa Pharmaceuticals International, plc | A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease |
| NCT03827018 | phase2 | completed | 2018-09-20 | 2020-08-13 | Kiniksa Pharmaceuticals, Ltd. | KPL-301 for Subjects With Giant Cell Arteritis |
| NCT07010159 | phase2_3 | recruiting | 2025-07-25 | 2027-12-31 | Kiniksa Pharmaceuticals International, plc | Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387 |
| NCT04447469 | phase2_3 | completed | 2020-07-28 | 2021-11-12 | Kiniksa Pharmaceuticals International, plc | Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125249 | 2008-02-27 | BLA | KINIKSA PHARMACEUTICALS (UK), LTD. | |||||
Loading… | ||||||||